Neuropeptide Y receptors: a promising target for cancer imaging and therapy
- PMID: 26816643
- PMCID: PMC4669009
- DOI: 10.1093/rb/rbv013
Neuropeptide Y receptors: a promising target for cancer imaging and therapy
Abstract
Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y1, Y2, Y4 and Y5). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
Keywords: cancers; imaging; neuropeptide Y receptors; therapy.
Similar articles
-
Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat. Relationship to the Y5 'feeding' receptor.Brain Res. 1997 May 30;758(1-2):17-25. doi: 10.1016/s0006-8993(97)00160-1. Brain Res. 1997. PMID: 9203528
-
A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans.Cell Physiol Biochem. 2018;45(1):88-107. doi: 10.1159/000486225. Epub 2017 Dec 22. Cell Physiol Biochem. 2018. PMID: 29310113 Review.
-
Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.Neuropharmacology. 2003 Feb;44(2):282-92. doi: 10.1016/s0028-3908(02)00382-9. Neuropharmacology. 2003. PMID: 12623227
-
Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.Neuropeptides. 2004 Aug;38(4):163-74. doi: 10.1016/j.npep.2004.04.007. Neuropeptides. 2004. PMID: 15337369
-
Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.J Pept Sci. 2000 Mar;6(3):97-122. doi: 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E. J Pept Sci. 2000. PMID: 10759209 Review.
Cited by
-
Heterobivalent Dual-Target Peptide for Integrin-αvβ3 and Neuropeptide Y Receptors on Breast Tumor.Pharmaceuticals (Basel). 2024 Oct 4;17(10):1328. doi: 10.3390/ph17101328. Pharmaceuticals (Basel). 2024. PMID: 39458969 Free PMC article.
-
Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.Adv Sci (Weinh). 2023 Jul;10(21):e2300545. doi: 10.1002/advs.202300545. Epub 2023 May 5. Adv Sci (Weinh). 2023. PMID: 37147783 Free PMC article.
-
NPFFR2 Contributes to the Malignancy of Hepatocellular Carcinoma Development by Activating RhoA/YAP Signaling.Cancers (Basel). 2022 Nov 27;14(23):5850. doi: 10.3390/cancers14235850. Cancers (Basel). 2022. PMID: 36497331 Free PMC article.
-
Neurotransmitters: emerging targets in cancer.Oncogene. 2020 Jan;39(3):503-515. doi: 10.1038/s41388-019-1006-0. Epub 2019 Sep 16. Oncogene. 2020. PMID: 31527667 Review.
-
Nanomaterial-assisted pancreatic cancer theranostics.Regen Biomater. 2025 Jun 11;12:rbaf054. doi: 10.1093/rb/rbaf054. eCollection 2025. Regen Biomater. 2025. PMID: 40585530 Free PMC article. Review.
References
-
- Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;296:659–60. - PubMed
-
- Schwartz TW, Fuhlendorff J, Kjems LL, et al. Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann N Y Acad Sci 1990;611:35–47. - PubMed
-
- Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004;38:213–24. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous